Internal Medicine, Endocrinology, Diabetes, & Metabolism · Cincinnati, OH
NPI
1215193537
Since 2008
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
5050 E Galbraith Rd Ste B
Cincinnati, OH, 45236
Phone (513) 760-5511
Groups this clinician bills Medicare through
Medicare paid, 2024
$50K
1,019 services
Medicare patients, 2024
304
Average age 73
Drug cost, 2024
$2.9M
5,825 prescriptions
Company payments, 2025
$1,079
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jyothi M Joseph-Hayes was code 99214 (office e&m - established), 406 times for 246 patients. In total Jyothi M Joseph-Hayes billed 1,019 services in 12 codes, and Medicare paid $50K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-08-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 406 | 246 | $65.99 | $27K |
| 95251 Test - Miscellaneous | Office | 236 | 101 | $25.51 | $6,020 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 174 | 141 | $10.78 | $1,875 |
| 99215 Office E&M - Established | Office | 106 | 84 | $106.37 | $11K |
| 99213 Office E&M - Established | Office | 54 | 50 | $42.53 | $2,297 |
| 36415 Venipuncture Blood Collection | Office | 18 | 11 | $8.65 | $156 |
By year: 2022 $55K for 849 services; 2023 $45K for 840 services; 2024 $50K for 1,019 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 18 | 11 | $8.65 | $156 |
Medicare prescription drug claims, 2024
In 2024, the drug Jyothi M Joseph-Hayes prescribed most often to Medicare patients was Levothyroxine Sodium, with 628 prescriptions and refills. In total Jyothi M Joseph-Hayes wrote 5,825 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 628 | 1,788 | 175 | $5,765 |
| Mounjaro Tirzepatide | 387 | 499 | 69 | $522K |
| Ozempic Semaglutide | 352 | 473 | 55 | $441K |
| Tresiba Flextouch U-200 Insulin Degludec | 288 | 446 | 61 | $388K |
| Metformin Hcl Generic | 257 | 687 | 70 | $1,377 |
| Synthroid Levothyroxine Sodium | 224 | 603 | 51 | $17K |
| Metformin Hcl Er Metformin Hcl | 201 | 563 | 58 | $1,585 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 183 | 449 | 67 | $22K |
| Glipizide Generic | 171 | 496 | 53 | $1,297 |
| Jardiance Empagliflozin | 168 | 367 | 38 | $205K |
| Humalog Kwikpen U-200 Insulin Lispro | 150 | 198 | 28 | $230K |
| Tresiba Flextouch U-100 Insulin Degludec | 140 | 298 | 44 | $92K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 128 | 252 | 38 | $19K |
| Liothyronine Sodium Generic | 123 | 361 | 34 | $7,842 |
| Novolog Flexpen Insulin Aspart | 119 | 233 | 43 | $33K |
Brand drugs: 3,493 claims; generic drugs: 1,713 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jyothi M Joseph-Hayes $1,079 ($1,079 in general payments such as food, travel and fees) from 22 companies. The largest payer was Dexcom, Inc. with $215.
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. DXCM | 5 | $215 |
| Sequel Med Tech, LLC | 1 | $93.93 |
| Novo Nordisk Inc NVO | 4 | $76.84 |
| Alexion Pharmaceuticals, Inc. AZN | 3 | $75.34 |
| Kyowa Kirin, Inc. 4151.T | 3 | $57.49 |
| Madrigal Pharmaceuticals MDGL | 2 | $54.79 |
| Lilly USA, LLC LLY | 3 | $52.93 |
| Abbott Laboratories ABT | 1 | $48.03 |
| CeQur Corporation | 1 | $44.4 |
| Insulet Corporation PODD | 2 | $42.83 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.